New opportunities in the diagnosis and treatment of inflammatory bowel diseases

The study of inflammatory bowel disease is characterized by dynamism and new discoveries. Subtle and new mechanisms of participation of genetic and environmental factors in the pathogenesis of inflammatory bowel diseases have been deciphered, as well as new classes of drugs have appeared that allow influencing many parts of the inflammatory process. However, the paradox of the situation lies in the fact that the more recent advances and discoveries in the field of biology and medicine, the more “gray spots” become in our understanding of the pathogenesis and approaches to the treatment of this category of patients. At the same time, the fundamental problems of IBD, related to reducing the risk of surgical interventions and restoring the quality of life of patients to the population level, are far from being resolved. The article discusses new methodological approaches to the treatment of patients with inflammatory bowel diseases using new classes of cytostatics and granulocyte-macrophage colony-stimulating factors.